Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
22
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 22 publications
(24 citation statements)
references
References 24 publications
1
22
1
Order By: Relevance
“…29,30 Yoshida et al 31 associated PD-L1 overexpression in TSCC pT1 and pT2 tumors with an increasing risk of lymph node metastasis while other reports indicate natural killer cell suppression and a higher risk of local recurrence in PD-L1-overexpressing TSCC. 32,33 In line with previous reports, we observed notably higher levels of PD-L1 in the TSCC compared to normal tongue tissues, which correlated to lymphatic metastasis and advanced staging. As shown in a study on breast cancer, 34 we also hypothesize that the increased risk of lymph node metastasis accompanying PD-L1 overexpression is due to the high surface expression of its cognate receptor PD-1 on lymphocytes.…”
Section: Discussionsupporting
confidence: 91%
“…29,30 Yoshida et al 31 associated PD-L1 overexpression in TSCC pT1 and pT2 tumors with an increasing risk of lymph node metastasis while other reports indicate natural killer cell suppression and a higher risk of local recurrence in PD-L1-overexpressing TSCC. 32,33 In line with previous reports, we observed notably higher levels of PD-L1 in the TSCC compared to normal tongue tissues, which correlated to lymphatic metastasis and advanced staging. As shown in a study on breast cancer, 34 we also hypothesize that the increased risk of lymph node metastasis accompanying PD-L1 overexpression is due to the high surface expression of its cognate receptor PD-1 on lymphocytes.…”
Section: Discussionsupporting
confidence: 91%
“…However, we did not find such patterns in our samples. It is also worth mentioning that PD-L1 staining in nuclei of tumor cells (Naruse et al, 2019) is likely an artifact resulting from inappropriate sample treatment (Polioudaki et al, 2019) and nuclear staining was not seen in our samples.…”
Section: Circulating Pd-l1mentioning
confidence: 83%
“…Using our methodology, PD-L1-positive tumor cells were seen in 79% and PD-L1-positive immune cells in 96% of the samples. Previous studies focusing on patients with SCCOT have reported PD-L1 positivity in 23% (Yoshida et al, 2018), 57.9% (Naruse et al, 2019), or 79% (Mattox et al, 2017) of patients. In addition to intra-tumor heterogeneity of PD-L1 (Rasmussen et al, 2019), such differences between studies are most probably due to the different IHC antibodies/detection protocols and the different scoring criteria used.…”
Section: Circulating Pd-l1mentioning
confidence: 91%
See 1 more Smart Citation
“…A subsequent prospective study at the same institution found that 39% of patients receiving neoadjuvant chemotherapy had evidence of a major histologic response at the tongue primary site and this was associated with improved prognosis. In another recent retrospective study of oral tongue SCCA patients treated with neoadjuvant chemotherapy prior to surgery, Naruse et al discovered that patients who received neoadjuvant treatment and had higher expression of PD‐1/PD‐L1 immune checkpoint molecules demonstrated higher rates of local recurrence than patients who did not receive chemotherapy, implying another complex treatment consideration exists with regard to how manipulating the local immune response with other therapeutic modalities may have unintended effects on disease progression …”
Section: Discussionmentioning
confidence: 99%